1 |
D. Hoyer, D.E. Clarke, J.R. Fozard, P.R. Hartig, G.R. Martin, E.J. Mylecharrane, P.R. Saxena and P.P.A. Humphrey. Internation Union of Pharmacology classification of receptors for hydroxytryptamine (serotonin). Pharmacol. Rev., 46, 157-204 (1994).
|
2 |
D. Hoyer and G.R. Martin. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology, 36, 419-428 (1997).
DOI
ScienceOn
|
3 |
L.H. Tecott, L.M. Sun, S.F. Akana, A.M. Strack, D.H. Lowenstein, M.F. Dallman and D. Julius. Eating disorders and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature, 374 (6522), 542-546 (1995).
DOI
ScienceOn
|
4 |
L.H. Tecott and L. Abdallah. Mouse genetic approaches to feeding regulation: serotonin 5-HT2C receptor mutant mice. CNS Spectr., 8, 584-588 (2003).
|
5 |
D. Murphy and K.P. Lesch. Targeting the murine serotonin transporter: insights into human neurobiology (Reviews). Nature Rev./Neurosci., 9, 85-96 (2008).
DOI
ScienceOn
|
6 |
A.N. Pae, H. Choo, Y.S. Cho, S. A. Jun, H.J. Cho, W.K. Park and J.M. Kim, Novel sulfonamide derivatives as 5-HT2a/2c receptors antagonist and serotonin reuptake inhibitors and preparation thereof. Patent submitted (2009).
|
7 |
S.M. Bromidge, S.E. Clarke, T. Gager, K. Griffith, P. Jeffrey, A.J. Jennings, G.F. Joiner, F.D. King, P.J. Lovell, S.F Moss, H. Newman, G. Riley, D. Rogers, C. Routledge, H. Serafinowska and D.R. Smith. Phenyl benzenesulfonamides are novel and selective antagonists: Identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134). Bioorg. Med. Chem. Lett. 11, 55-58 (2001).
DOI
ScienceOn
|
8 |
M. Issac. Serotonergic 5-HT2c receptors as a potential therapeutic target for the design of antiepileptic drugs. Curr. Top Med. Chem., 5, 59-67 (2005).
DOI
ScienceOn
|
9 |
G. Di Giovanni, V. Matteo, M. Pierucci, A. Benigno and E. Espoito. Central serotoinin 2C receptor: from physiology to pathology. Curr. Top Med. Chem., 6, 1909-1925 (2006).
DOI
ScienceOn
|
10 |
M.G. Frank, M.P. Stryker and L.H. Tecott. Sleep and sleep homeostasis in mice lacking the 5-HT2c receptor. Neuropharmacology , 27, 869-873 (2002).
DOI
|
11 |
J.T. DiPiro, W.J. Spruill, W.E. Wade, R.A. Blouin and J.M. Pruemer. Half-life, elimination rate and AUC: In Concept in Clinical Pharmacokinetics (4th Ed.), American Society of Health-System Pharmacists, pp. 29-44 (2005).
|
12 |
M.J. Millan. Serotonin 5-HT2c receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie, 60, 441-460 (2005).
DOI
|
13 |
R.A.H. Adan, L.J.M.J. Vanderschuren and S.E. La Fleur. Antiobesity drugs and neural circuits of feeding. Trends .Pharmacol. Sci., 29 (4), 208-217 (2008).
DOI
ScienceOn
|